ZA963735B - High-dose chromic picolinate treatment of type ii diabetes - Google Patents
High-dose chromic picolinate treatment of type ii diabetesInfo
- Publication number
- ZA963735B ZA963735B ZA963735A ZA963735A ZA963735B ZA 963735 B ZA963735 B ZA 963735B ZA 963735 A ZA963735 A ZA 963735A ZA 963735 A ZA963735 A ZA 963735A ZA 963735 B ZA963735 B ZA 963735B
- Authority
- ZA
- South Africa
- Prior art keywords
- diabetes
- dose
- type
- chromic picolinate
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/440,362 US6329361B1 (en) | 1995-05-12 | 1995-05-12 | High-dose chromic picolinate treatment of type II diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA963735B true ZA963735B (en) | 1997-01-09 |
Family
ID=23748461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA963735A ZA963735B (en) | 1995-05-12 | 1996-05-10 | High-dose chromic picolinate treatment of type ii diabetes |
Country Status (15)
Country | Link |
---|---|
US (1) | US6329361B1 (xx) |
EP (1) | EP0825861B1 (xx) |
JP (1) | JP3699124B2 (xx) |
AR (1) | AR004486A1 (xx) |
AT (1) | ATE227127T1 (xx) |
AU (1) | AU5733796A (xx) |
BR (1) | BR9608835A (xx) |
DE (1) | DE69624699T2 (xx) |
DK (1) | DK0825861T3 (xx) |
ES (1) | ES2183952T3 (xx) |
IL (1) | IL118222A (xx) |
PT (1) | PT825861E (xx) |
RU (1) | RU2195934C2 (xx) |
WO (1) | WO1996035421A1 (xx) |
ZA (1) | ZA963735B (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
EP1001793B1 (en) * | 1997-08-08 | 2005-09-14 | Nutrition 21 | Chromium/biotin treatment of type ii diabetes |
EP0925790A1 (en) * | 1997-12-17 | 1999-06-30 | Kartar Dr. Lalvani | Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM) |
US5932258A (en) * | 1998-04-06 | 1999-08-03 | The Iams Company | Composition and process for improving glucose metabolism in companion animals |
US5948772A (en) * | 1998-08-28 | 1999-09-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
US6143301A (en) | 1998-08-28 | 2000-11-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
US5905075A (en) * | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
CA2344246A1 (en) | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
US6376549B1 (en) | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
DE60104450T2 (de) | 2000-09-21 | 2005-09-15 | Nutrition 21, Inc. | Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils |
US20050214384A1 (en) * | 2002-04-23 | 2005-09-29 | Vijaya Juturu | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
US20060134228A1 (en) * | 2002-05-14 | 2006-06-22 | Nipro Corporation | Medicine for prevention of and treatment for amyloidosis |
US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
US20050019435A1 (en) * | 2003-07-21 | 2005-01-27 | Jeffrey Young | Method of treating non-insulin dependent diabetes mellitus and related complications |
US20050085454A1 (en) * | 2003-10-16 | 2005-04-21 | Natreon Inc. | Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance |
CA2931881C (en) * | 2007-01-31 | 2018-12-11 | Nutrition 21, Inc. | Use of chromium histidinate for treatment of cardiometabolic disorders |
ES2841379T3 (es) | 2007-03-13 | 2021-07-08 | Jds Therapeutics Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
EP2448412B1 (en) | 2009-07-01 | 2019-05-01 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
KR101836957B1 (ko) | 2011-03-01 | 2018-03-09 | 제이디에스 테라퓨틱스, 엘엘씨 | 당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물 |
WO2016130981A1 (en) | 2015-02-13 | 2016-08-18 | Mars, Incorporated | Pet food feeding system |
MX2018009748A (es) | 2016-02-11 | 2019-02-07 | Nutrition 21 Llc | Composiciones que contienen cromo para mejorar la salud y el estado físico. |
US10820617B1 (en) | 2018-03-29 | 2020-11-03 | Government Of The United States, As Represented By The Secretary Of The Air Force | All inclusive electrolytes, vitamins, and protein powder training supplement |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315927A (en) * | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US5164384A (en) | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
-
1995
- 1995-05-12 US US08/440,362 patent/US6329361B1/en not_active Expired - Lifetime
-
1996
- 1996-05-08 JP JP53421996A patent/JP3699124B2/ja not_active Expired - Lifetime
- 1996-05-08 BR BR9608835-4A patent/BR9608835A/pt not_active IP Right Cessation
- 1996-05-08 DE DE69624699T patent/DE69624699T2/de not_active Expired - Fee Related
- 1996-05-08 DK DK96915595T patent/DK0825861T3/da active
- 1996-05-08 EP EP96915595A patent/EP0825861B1/en not_active Expired - Lifetime
- 1996-05-08 AU AU57337/96A patent/AU5733796A/en not_active Abandoned
- 1996-05-08 PT PT96915595T patent/PT825861E/pt unknown
- 1996-05-08 RU RU97120726/14A patent/RU2195934C2/ru not_active IP Right Cessation
- 1996-05-08 WO PCT/US1996/006493 patent/WO1996035421A1/en active IP Right Grant
- 1996-05-08 ES ES96915595T patent/ES2183952T3/es not_active Expired - Lifetime
- 1996-05-08 AT AT96915595T patent/ATE227127T1/de not_active IP Right Cessation
- 1996-05-10 IL IL11822296A patent/IL118222A/xx not_active IP Right Cessation
- 1996-05-10 AR ARP960102526A patent/AR004486A1/es unknown
- 1996-05-10 ZA ZA963735A patent/ZA963735B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0825861B1 (en) | 2002-11-06 |
DK0825861T3 (da) | 2003-03-03 |
ES2183952T3 (es) | 2003-04-01 |
JP3699124B2 (ja) | 2005-09-28 |
AR004486A1 (es) | 1998-12-16 |
IL118222A (en) | 2000-06-01 |
AU5733796A (en) | 1996-11-29 |
BR9608835A (pt) | 1999-12-07 |
WO1996035421A1 (en) | 1996-11-14 |
RU2195934C2 (ru) | 2003-01-10 |
DE69624699D1 (de) | 2002-12-12 |
MX9708628A (es) | 1998-06-28 |
DE69624699T2 (de) | 2003-03-20 |
IL118222A0 (en) | 1996-09-12 |
ATE227127T1 (de) | 2002-11-15 |
EP0825861A1 (en) | 1998-03-04 |
US6329361B1 (en) | 2001-12-11 |
PT825861E (pt) | 2003-03-31 |
JPH11504941A (ja) | 1999-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA963735B (en) | High-dose chromic picolinate treatment of type ii diabetes | |
GB2298440B (en) | Well treatment | |
PL324284A1 (en) | Methods of treating diabetes | |
ZA96740B (en) | Skin treatment composition | |
HU9603369D0 (en) | Treatment of vegetables | |
AU7772794A (en) | Treatment of obesity | |
GB9519033D0 (en) | Treatment | |
AU7166896A (en) | Cancer treatment | |
AU7484596A (en) | Combination therapy for the treatment of diabetes and obesity | |
GB2303303B (en) | Medical treatment | |
GB9521725D0 (en) | Medical treatment | |
GB9502136D0 (en) | Treatment of waste | |
AUPN221195A0 (en) | Combined waste treatment | |
AU6829696A (en) | Treatment of solutions | |
GB9526264D0 (en) | Medical treatment | |
GB2304046B (en) | Diabetes therapy | |
GB2307858B (en) | Medical treatment | |
ZA961060B (en) | Treatment of titanium-containing material | |
GB9503201D0 (en) | Anti-smoking treatment,therapy and illness prevention | |
GB9608631D0 (en) | Medical treatment | |
GB9503143D0 (en) | Treatment of depression | |
GB9510065D0 (en) | Treatment | |
AU3450995A (en) | Effluent treatment | |
AUPN323395A0 (en) | Effluent treatment | |
AUPO948597A0 (en) | Treatment of cyanide wastes |